Bvf Partners L. P/Il Sells 500,742 Shares of XOMA Co. (NASDAQ:XOMA) Stock

XOMA Co. (NASDAQ:XOMA) major shareholder Bvf Partners L. P/Il sold 500,742 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

XOMA Stock Down 2.9 %

NASDAQ XOMA traded down $0.78 during mid-day trading on Tuesday, reaching $26.48. 11,377 shares of the company’s stock traded hands, compared to its average volume of 69,228. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA Co. has a 1-year low of $19.50 and a 1-year high of $35.00. The company has a fifty day simple moving average of $28.13 and a 200-day simple moving average of $28.12. The company has a market cap of $311.93 million, a price-to-earnings ratio of -7.61 and a beta of 0.92.

XOMA (NASDAQ:XOMA) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.05. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The company had revenue of $7.20 million during the quarter, compared to analyst estimates of $6.66 million. As a group, equities research analysts expect that XOMA Co. will post -1.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on XOMA shares. StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a research report on Thursday, January 16th. HC Wainwright reissued a “buy” rating and set a $123.00 price target on shares of XOMA in a research report on Tuesday, January 7th.

Hedge Funds Weigh In On XOMA

Several hedge funds have recently modified their holdings of XOMA. Geode Capital Management LLC raised its position in shares of XOMA by 0.6% during the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock worth $4,840,000 after purchasing an additional 1,138 shares during the period. State Street Corp grew its position in XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after purchasing an additional 1,754 shares in the last quarter. Ellsworth Advisors LLC acquired a new position in shares of XOMA in the third quarter worth $516,000. Barclays PLC increased its position in XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 8,447 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares in the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.